In de novo molecular design, we seek to produce novel molecule libraries that meet required property profiles. Our aim is to create generative statistical models for molecular data that can capture the distributions of molecular compounds and generate a new set of valid compounds with the desired property requirements. Some notable advances in complete de novo drug design are established by Segler et al. and Gupta et al. ; they introduce generative recurrent networks, which are trained on a large and diverse data set to recognize general features of molecules and fine-tuned on a smaller focused set active towards the desired target. Brown et al. and Polykovsky et al. attempt to compose standardized benchmarking frameworks with various generative models as well as distribution and property-based evaluation metrics.